Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent's corporate responsibility strategy – People, Environment, and Community. The report also outlines the company's future commitments as it progresses its mission to help people lead better and healthier lives. O.

Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

Builders FirstSource

Disney

Fortinet

Juniper Networks

Tapestry

Targa Resources

Uber

Missed big runs in some S&P 500 stocks? Don't worry — it's not too late.

8 Stocks Already Up Big This Year Will Rise Even More, Analysts

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalent, Inc. (NYSE: CTLT) to Novo Holdings. Under the terms of the proposed transaction, shareholders of Catalent will receive $63.50 in cash for each share of Catalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the considerat.

CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT

Catalent has reduced its headcount by about 300 employees as part of its ongoing restructuring plans, the company disclosed in a regulatory filing on Wednesday.

Wegovy packing supplier Catalent lays off 300 workers

Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.

Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Novo Nordisk

Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's parent firm.

Catalent Q2 sales inch past estimates amid takeover by Novo Holdings

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023. “I am proud of the progress the Catalent team made in our second quarter and our ongoing momentum, including strong non-COVID sequential revenue growth in both the Biologics and PCH segments. We also continued to invest in our operational.

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

AstraZeneca

Astrazeneca on Thursday said the sale of contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance of building an independent supply chain.

Astrazeneca says Catalent deal shows importance of in-house capacity

The European Union's drugs regulator said on Wednesday it will investigate any risks to the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk , part of its mandate to prevent drug shortages.

EU watchdog is looking into availability of drugs made at Catalent sites sold to Novo

Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.

Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings

U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent , including discovery of a "pest" on the manufacturing line, according to an inspection report.

US FDA finds control lapses at Catalent plant being sold to Novo

Novo Nordisk (NYSE:NVO)'s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts say, and will help meet demand for its flagship weight loss drugs. Though Catalent already provides two filling lines for Novo's injectable Wegovy drug in Belgium and the US, transfer of ownership will see production capacity increase further, according to JP Morgan analysts, eventually also including the Ozempic treatment.

Novo Nordisk acquisition of Catalent production sensible, analysts say

Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?

The pharmaceuticals manufacturing leader is being acquired by Novo Holdings. The transaction should close toward the end of 2024.

Why Catalent Stock Soared Today

The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5 billion.

Novo Holdings Buyout Sends Catalent Stock Surging

Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.

Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal

Catalent (NYSE: CTLT ) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE: NVO ) parent Novo Holdings for $16.5 billion. The transaction will have Novo Holdings paying $63.50 per share in cash for CTLT stock.

Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk

Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.

Novo Nordisk To Up Production Capacity As Parent Buys Catalent

Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.

Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply

MILWAUKEE , Feb. 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Catalent (NYSE: CTLT)  for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Holdings. Click here to learn how to join the https://www.ademilaw.com/case/catalent-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Catalent, Inc. has obtained a Fair Price in its transaction with Novo Holdings

Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)'s controlling shareholder was to buy the firm for US$16.5 billion. Novo Holdings, which owns a majority stake in the weight loss drug maker, unveiled the takeover on Monday, which includes assumed debt and, at US$63.50 a share, represents a 16.5% premium on Catalent's Friday closing price.

Catalent surges on $16.5 billion takeover by Novo Nordisk shareholder

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Catalent (NYSE:CTLT) breached their fiduciary duties in connection with the proposed sale of the Company to Novo Holdings. You can click on the following link to join this investigation: Click Here to Join the Investigation On February 5, 2024, Catalent announced that it had entered a deal to merge with Novo Holdings. Under the terms of the deal, Catalent s.

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Catalent; Is $63.50 a Fair Price?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Catalent, Inc. (NYSE: CTLT) to Novo Holdings for $63.50 per share in cash is fair to Catalent shareholders. Halper Sadeh encourages Catalent shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Catalent and its boar.

CTLT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Catalent, Inc. Is Fair to Shareholders

The controlling shareholder of Wegovy maker Novo Nordisk is buying Catalent in a deal that values the U.S. drug company at $16.5 billion, including debt.

News for Catalent Stock (CTLT)